Twinlab Fuel announces support for Ranger 2008 competition
AMERICAN FORK, Utah Twinlab Fuel, a division of supplement manufacturer ISI Brands, announced Friday its support of the Best Ranger Competition 2008, the 25th anniversary of the competition that recognizes the best two-man “buddy” team in United States Armed Forces.
“We have incredible respect for the men and women in the Armed Forces and are looking forward to being part of this proud tradition,” stated Mark Fox, president of ISI Brands. The endurance event kicked off Friday and ends Sunday.
J&J posts record sales for Q1
NEW BRUNSWICK, N.J. Johnson & Johnson released its first quarter 2008 sales results and it showed that the company had record sales for the quarter of $16.2 billion. This was a 7.7 percent increase as compared to the first quarter of 2007. Net earnings for the quarter were $3.6 billion.
Sales growth reflects the strong performance of Remicade, a biologic approved for the treatment of a number of immune mediated inflammatory diseases, which increased by 12.7 percent; and Concerta, a treatment for attention deficit hyperactivity disorder, which increased by 12 percent.
Sales though were also negatively affected by the proton pump inhibitor Aciphex, which saw sales decline by 27 percent, the pain patch Duragesic which fell by 35.3 percent, and the anemia drug Procrit, which fell by 37 percent.
Also during the quarter, the company announced that it received an approvable letter from the Food and Drug Administration regarding its application for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections, as well as submitting an application to the FDA for tapentadol hydrochloride immediate release tablets, an investigational oral analgesic for the relief of moderate to severe acute pain.
“We achieved solid earnings in the first quarter which reflects our continued focus on profitable growth for Johnson & Johnson,” said William Weldon, chairman and chief executive officer. “Our strategy of being broadly based remains one of the keys to our consistent long-term performance.”
Perrigo gets FDA approval for generic OTC Zyrtec
ALLEGAN, Mich. Perrigo earlier this week received final approval from the Food and Drug Administration to manufacture and market over-the-counter store-brand equivalents to McNeil Consumer’s Children’s Zyrtec oral solution, indicated for indoor and outdoor allergy and hives relief.
According to Wolters Kluwer data, brand sales for the original prescription strength version of the product for the last 12 months ending December 2007 were approximately $80 million.
Perrigo expects to begin shipping the product immediately.